Literature DB >> 29395287

Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.

Philippe Bulens1, Alice Couwenberg2, Karin Haustermans3, Annelies Debucquoy1, Vincent Vandecaveye4, Marielle Philippens2, Mu Zhou5, Olivier Gevaert5, Martijn Intven2.   

Abstract

BACKGROUND AND
PURPOSE: To safely implement organ preserving treatment strategies for patients with rectal cancer, well-considered selection of patients with favourable response is needed. In this study, we develop and validate an MRI-based response predicting model.
METHODS: A multivariate model using T2-volumetric and DWI parameters before and 6 weeks after chemoradiation (CRT) was developed using a cohort of 85 rectal cancer patients and validated in an external cohort of 55 patients that underwent preoperative CRT.
RESULTS: Twenty-two patients (26%) achieved ypT0-1N0 response in the development cohort versus 13 patients (24%) in the validation cohort. Two T2-volumetric parameters (ΔVolume% and Sphere_post) and two DWI parameters (ADC_avg_post and ADCratio_avg) were retained in a model predicting (near-)complete response (ypT0-1N0). In the development cohort, this model had a good predictive performance (AUC = 0.89; 95% CI 0.80-0.98). Validation of the model in an external cohort resulted in a similar performance (AUC = 0.88 95% CI 0.79-0.98).
CONCLUSION: An MRI-based prediction model of (near-)complete pathological response following CRT in rectal cancer patients, shows a high predictive performance in an external validation cohort. The clinically relevant features in the model make it an interesting tool for implementation of organ-preserving strategies in rectal cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; DWI; MRI; Rectal cancer; Response prediction

Mesh:

Year:  2018        PMID: 29395287      PMCID: PMC5990635          DOI: 10.1016/j.radonc.2018.01.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  32 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy.

Authors:  Ann M Hanly; Elizabeth M Ryan; Ailín C Rogers; Deborah A McNamara; Robert D Madoff; Desmond C Winter
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

3.  Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Zhenyu Liu; Xiao-Yan Zhang; Yan-Jie Shi; Lin Wang; Hai-Tao Zhu; Zhenchao Tang; Shuo Wang; Xiao-Ting Li; Jie Tian; Ying-Shi Sun
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

4.  Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.

Authors:  Eric Rullier; Philippe Rouanet; Jean-Jacques Tuech; Alain Valverde; Bernard Lelong; Michel Rivoire; Jean-Luc Faucheron; Mehrdad Jafari; Guillaume Portier; Bernard Meunier; Igor Sileznieff; Michel Prudhomme; Frédéric Marchal; Marc Pocard; Denis Pezet; Anne Rullier; Véronique Vendrely; Quentin Denost; Julien Asselineau; Adélaïde Doussau
Journal:  Lancet       Date:  2017-06-07       Impact factor: 79.321

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

Review 6.  The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.

Authors:  Ines Joye; Christophe M Deroose; Vincent Vandecaveye; Karin Haustermans
Journal:  Radiother Oncol       Date:  2014-11       Impact factor: 6.280

7.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Authors:  D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis
Journal:  Br J Surg       Date:  2013-03-27       Impact factor: 6.939

8.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

9.  Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy.

Authors:  M Intven; O Reerink; M E P Philippens
Journal:  Strahlenther Onkol       Date:  2012-12-19       Impact factor: 3.621

10.  Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI.

Authors:  Ke Nie; Liming Shi; Qin Chen; Xi Hu; Salma K Jabbour; Ning Yue; Tianye Niu; Xiaonan Sun
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

View more
  6 in total

1.  Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics.

Authors:  Philippe Bulens; Alice Couwenberg; Martijn Intven; Annelies Debucquoy; Vincent Vandecaveye; Eric Van Cutsem; André D'Hoore; Albert Wolthuis; Pritam Mukherjee; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

2.  Accurate outcome prediction after neo-adjuvant radio-chemotherapy for rectal cancer based on a TCP-based early regression index.

Authors:  Claudio Fiorino; Paolo Passoni; Anna Palmisano; Calogero Gumina; Giovanni M Cattaneo; Sara Broggi; Alessandra Di Chiara; Antonio Esposito; Martina Mori; Monica Ronzoni; Riccardo Rosati; Najla Slim; Francesco De Cobelli; Riccardo Calandrino; Nadia G Di Muzio
Journal:  Clin Transl Radiat Oncol       Date:  2019-07-03

3.  Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation.

Authors:  Dorian Gottwald; Florian Putz; Nora Hohmann; Maike Büttner-Herold; Markus Hecht; Rainer Fietkau; Luitpold Distel
Journal:  BMC Mol Cell Biol       Date:  2020-11-07

4.  Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Xinyu Shi; Min Zhao; Bo Shi; Guoliang Chen; Huihui Yao; Junjie Chen; Daiwei Wan; Wen Gu; Songbing He
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

5.  Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer.

Authors:  Gyu Sang Yoo; Hee Chul Park; Jeong Il Yu; Doo Ho Choi; Won Kyung Cho; Young Suk Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Woo Yong Lee; Hee Cheol Kim; Seong Hyeon Yun; Yong Beom Cho; Yoon Ah Park; Kyoung Doo Song; Seok-Hyung Kim; Sang Yun Ha
Journal:  Cancer Res Treat       Date:  2019-09-25       Impact factor: 4.679

6.  A Deep Learning Model to Predict the Response to Neoadjuvant Chemoradiotherapy by the Pretreatment Apparent Diffusion Coefficient Images of Locally Advanced Rectal Cancer.

Authors:  Hai-Tao Zhu; Xiao-Yan Zhang; Yan-Jie Shi; Xiao-Ting Li; Ying-Shi Sun
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.